(UroToday.com) Conventional imaging modalities including computed tomography and bone scintigraphy are routinely recommended for prostate cancer staging, however, they are limited by relatively low sensitivity and moderate specificity. In contrast, PSMA-based imaging is highly promising for prostate cancer detection, with higher sensitivity, specificity, and accuracy. 18F-DCFPyL is a novel PSMA-targeted radiopharmaceutical for positron emission tomography (PET) being explored in the staging of prostate cancer. Previously, at AUA 2020, the diagnostic performance, detection rate, and potential impact of 18F-DCFPyL on the staging of patients with high- risk prostate cancer was reported. In a plenary abstract presentation in the Poster Highlights Session: Prostate Cancer session at the 2021 ASCO GU Cancers Symposium, Dr. Jeremy Durack and colleagues report on the impact of 18F-DCFPyL on the staging of patients with prostate cancer recurrence or metastases on conventional imaging.